The relationship between allergen immunotherapy and omalizumab for treating asthma

Expert Review of Respiratory Medicine

Volumn 9, Issue 2, 2015, Pages 129-134

  Braido, Fulvio ^a   Corsico, Angelo ^b   Rogkakou, Anthi ^a   Ronzoni, Vanessa ^b   Baiardini, Ilaria ^a   Canonica, Giorgio Walter ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

asthma; IgE; omalizumab; outcomes; specific immunotherapy

Indexed keywords

ALLERGEN; OMALIZUMAB; POLLEN ANTIGEN; ANTIASTHMATIC AGENT; IMMUNOGLOBULIN E;

ALLERGEN SPECIFIC IMMUNOTHERAPY; ALLERGIC ASTHMA; ARTICLE; ASTHMA; CLINICAL RESEARCH; DISEASE CONTROL; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; HUMAN; IMMUNOTHERAPY; MULTICENTER STUDY (TOPIC); NONHUMAN; PHENOTYPE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SUBCUTANEOUS IMMUNOTHERAPY; UNSPECIFIED SIDE EFFECT; ADVERSE EFFECTS; ANIMAL; DESENSITIZATION; IMMUNOLOGY; PROCEDURES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ALLERGENS; ANIMALS; ANTI-ASTHMATIC AGENTS; ASTHMA; DESENSITIZATION, IMMUNOLOGIC; HUMANS; IMMUNOGLOBULIN E; OMALIZUMAB; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84925010869     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.2015.1000866     Document Type: Article

References (30)

1. Burks AW, Calderon MA, Casale T, et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol 2013;131:1288-96.e3
2. Bousquet J, Schunemann HJ, Samolinski B, et al. Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs. J Allergy Clin Immunol 2012;130:1049-62
3. Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010;126:466-76
4. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev 2010 (8):CD001186
5. Erekosima N, Suarez-Cuervo C, Ramanathan M, et al. Effectiveness of subcutaneous immunotherapy for allergic rhinoconjunctivitis and asthma: A systematic review. Laryngoscope 2014;124:616-27
6. Mosbech H, Deckelmann R, de Blay F, et al. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: A randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2014;134(3):568-75
7. Chelladurai Y, Lin SY. Effectiveness of subcutaneous versus sublingual immunotherapy for allergic rhinitis: current update. Curr Opin Otolaryngol Head Neck Surg 2014;22:211-15
8. Bernstein DI, Wanner M, Borish L, Liss GM; Immunotherapy Committee, American Academy of Allergy, Asthma and Immunology. Twelve-year survey of fatal reactions to allergeninjections and skin testing: 1990-2001. J Allergy Clin Immunol 2004;113:1129-36
9. Riccio AM, Dal Negro RW, Micheletto C, et al. Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients. Int J Immunopathol Pharmacol 2012;25(2): 475-84
10. Mauri P, Riccio AM, Rossi R, et al. Proteomics of bronchial biopsies: Galectin-3 as a predictive biomarker of airway remodelling modulation in omalizumab-treated severe asthma patients. Immunol Lett 2014;162(1 Pt A):2-10
11. Marcus P; Practice Management Committee, American College of Chest Physicians. Incorporating anti-IgE (omalizumab) therapy into pulmonary medicine practice: practice management implications. Chest 2006;129:466-74
12. Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60:309-16
13. Masoli M, Fabian D, Holt S, Beasley R; Global Initiative for Asthma (GINA) Program Allergy. The global burden of asthma: executive summary of the GINA Dissemination Committee report. 2004;59:469-78
14. Variations in the prevalence of respiratory symptoms, self-reported asthma attacks, and use of asthma medication in the European Community Respiratory Health Survey (ECRHS). Eur Respir J 1996;9:687-95
15. Peters SP, Ferguson G, Deniz Y, Reisner C. Uncontrolled asthma: A review of the prevalence, disease burden and options for treatment. Respir Med 2006;100:1139-51
16. Cazzoletti L, Marcon A, Corsico A, Therapy and Health Economics Group of the European Community Respiratory Health Survey. Asthma severity according to Global Initiative for Asthma and its determinants: An international study. Int Arch Allergy Immunol 2010;151:70-9
17. Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet 2006;368:804-13
18. Buhl R, Marco AG, Cohen D, Canonica GW. Eligibility for treatment with omalizumab in Italy and Germany. Respir Med 2014;108:50-6
19. Casale TB, Busse WW, Kline JN, et al. Immune Tolerance Network Group. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2006;117:134-40. The authors showed in this double-blind placebo-controlled trial that omalizumab pretreatment enhances the safety of rush immunotherapy for ragweed allergic rhinitis.
20. Kuehr J, Brauburger J, Zielen S, et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 2002;109:274-80
21. Rolinck-Werninghaus C, Hamelmann E, Keil T, et al. The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children. Allergy 2004;59:973-9
22. Massanari M, Nelson H, Casale T, et al. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol 2010;125:383-9
23. Kopp MV, Hamelmann E, Bendiks M, DUAL study group. Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy. Pediatr Allergy Immunol 2013;24:427-33
24. Kopp MV, Hamelmann E, Zielen S, DUAL study group. Combination of omalizumab and specific immunotherapy issuperior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy 2009;39:271-9
25. Prussin C, Griffith DT, Boesel KM, et al. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol 2003;112:1147-54
26. MacGlashan DW Jr, Bochner BS, Adelman DC, et al. Down-regulation of fc (epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997;158:1438-45
27. Lin H, Boesel KM, Griffith DT, et al. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils. J Allergy Clin Immunol 2004;113:297-302
28. Bateman ED, Boushey HA, Bousquet J, GOAL Investigators Group. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004;170:836-44
29. Larenas-Linnemann D, Wahn U, Kopp M. Use of omalizumab to improve desensitization safety in allergen immunotherapy. J Allergy Clin Immunol 2014;133:937-7
30. Sanchez J, Ramirez R, Diez S, et al. Omalizumab beyond asthma. Allergol Immunopathol (Madr) 2012;40(5):306-15